ERC Consolidator Grant · 2020
REpurposing lung Surfactant Protein B for Inhalation therapy with RNA therapeutics
RESPIRNA aims to repurpose lung surfactant protein B (SP-B) to promote the cytosolic delivery of RNA in lung-related target cells. RNA therapeutics, including small interfering RNA (siRNA) and messenger RNA (mRNA), are poised to revolutionize medicine. However, despite a clear unmet medical need in many lung diseases, no RNA formulations are currently available for pulmonary administration. To unlock the full therapeutic potential of RNA drugs, safe and efficient nanomedicines that can deliver them inside target cells are required. SP-B is a key component of pulmonary surfactant, essential for mammalian breathing. In contrast to the general belief that pulmonary surfactant constitutes an…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.